Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital of Basel, Petersgraben 4, 4031, Basel, Switzerland.
Privaltklinik Obach, Solothurn, Switzerland.
Respir Res. 2021 Apr 20;22(1):114. doi: 10.1186/s12931-021-01704-0.
Obstructive sleep apnea (OSA) might lead to oxidative stress, inflammation and elevated circulating copeptin, proANP and proADM levels. We aimed to evaluate whether the levels of these prohormones are higher in patients with OSA and whether they might change under continuous positive airway pressure (CPAP) therapy, serving as potential proxies for the diagnosis and therapy-response in OSA.
A total of 310 patients with suspicion of OSA were recruited. Screening for OSA was performed using overnight pulse oximetry followed by polygraphy and a venous puncture in the morning. All patients diagnosed with OSA underwent CPAP adaptation. A venous puncture was conducted in the night before CPAP and in the following morning. At 1 and 6 months of treatment, polygraphy was performed, followed by a venous puncture in the morning. In the acquired blood, copeptin, proANP and proADM levels were measured.
We analyzed 232 patients with OSA and 30 patients without OSA. Our results indicated that only copeptin levels differed significantly among patients with and without OSA at baseline. In OSA patients, the levels of proADM significantly changed after 1 and 6 months on CPAP therapy, when compared to baseline (p < 0.001 and p = 0.020). Additionally, proANP levels significantly decreased after 12 h on CPAP therapy, as compared to baseline levels (p < 0.001).
Copeptin is significantly associated with the presence of OSA. ProANP levels might serve as a potential proxy for the acute response to non-invasive ventilation (12 h), while proADM reflects the long-term response (1 and 6 months).
阻塞性睡眠呼吸暂停(OSA)可能导致氧化应激、炎症和循环 copeptin、proANP 和 proADM 水平升高。我们旨在评估这些前激素水平在 OSA 患者中是否更高,以及它们在持续气道正压通气(CPAP)治疗下是否会发生变化,作为 OSA 诊断和治疗反应的潜在替代指标。
共招募了 310 例疑似 OSA 的患者。通过整夜脉搏血氧饱和度监测,随后进行多导睡眠图和清晨静脉穿刺,对 OSA 进行筛查。所有确诊为 OSA 的患者均接受 CPAP 适应性治疗。CPAP 治疗前一天晚上和第二天早上进行静脉穿刺。治疗 1 个月和 6 个月时,进行多导睡眠图检查,随后在早上进行静脉穿刺。采集血液,测量 copeptin、proANP 和 proADM 水平。
我们分析了 232 例 OSA 患者和 30 例无 OSA 患者。结果表明,仅基线时 OSA 患者和无 OSA 患者的 copeptin 水平存在显著差异。在 OSA 患者中,与基线相比,CPAP 治疗 1 个月和 6 个月后 proADM 水平显著变化(p<0.001 和 p=0.020)。此外,与基线相比,CPAP 治疗 12 小时后 proANP 水平显著降低(p<0.001)。
Copeptin 与 OSA 的存在显著相关。ProANP 水平可能作为急性无创通气反应(12 小时)的潜在替代指标,而 proADM 反映了长期反应(1 个月和 6 个月)。